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Abstract 
Background: Cardiovascular-related mortality is a major concern in NAFLD. 
Advanced fibrosis was known to be associated with cardiovascular diseases. NAFLD 
Fibrosis Score (NFS) is used to identify the development of liver fibrosis in NAFLD 
patients. Left ventricular mass index (LVMI) is a sign of subclinical cardiovascular 
complications in NAFLD. The correlation between NAFLD fibrosis score with LVMI 
in NAFLD patients is not fully established.  
Objective: To analyze the correlation between NAFLD fibrosis score with LVMI  in 
NAFLD patients.  
Methods: A cross-sectional study of NAFLD patients in Kariadi Hospital Indonesia. 
NFS was calculated using a formula based on clinical and biochemical parameters. 
LVMI was measured with echocardiography. Pearson’s, Mann-Whitney, and logistic 
regression were used for analysis. 
Results: A total of 64 patients with primary NAFLD were enrolled, 54.7% males and 
45.3% females. Mean age was 52.8 ± 10.5 years (30-77 years). Based on NFS criteria, 
the high probability group was most prevalent (50%), followed by intermediate 
probability group (34.4%) and low probability group (15.6%). Highest increase in 
LVMI was obtained in the high probability group (93.8%), followed by intermediate 
probability (59.1%), and low probability group (10%) respectively. There was 
significant correlation between NFS and LVMI (P 0.002). Logistic regression showed 
that NFS has a more significant correlation with LVMI compared to gender (P=0.002). 
Conclusion: NFS is a non‐invasive liver fibrosis score which independently correlates 
with Left ventricular mass index (LVMI), a marker of cardiovascular abnormality.  
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INTRODUCTION 
  Non-alcoholic fatty liver disease (NAFLD) is 
currently the main contributor of chronic liver disease 
and has a variety of clinical spectrum ranging from 
simple steatosis to non-alcoholic steatohepatitis 
(NASH). 
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 This condition often leads to fibrosis, cirrhosis, and 
malignancy.1 The prevalence rate of NAFLD in America 
reached up to 25 – 30% of the general population with 2 
– 3% of these patients suffering from NASH.2,3 A large 
prospective cohort study by Stephen et al, found that 
from middle-age Americans living in Texas, the 
prevalence of NAFLD was estimated to be at an 
approximate of 38%.4 Meanwhile, the current prevalence 
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around 5 – 30%.5,6 In Jakarta, the prevalence of NAFLD 
was approximately 30.6%.7 Based on the 
ultrasonography results obtained from the radiology 
department, the number of patients with NAFLD in dr. 
Kariadi hospital Semarang has also increased.8  
 NAFLD has been a ‘Western Disease’, however in 
the past two decades, urbanization in many Asian 
countries has led to a sedentary lifestyle and 
overnutrition, which is lead to the escalation of obesity 
and NAFLD cases.9 Clinical and epidemiological studies 
discovered that NAFLD is also correlated with an 
increased risk of coronary artery diseases, abnormality 
of heart function and structure (ventricular hypertrophy, 
ventricular dysfunction, heart failure), valvular heart 
disease (aortic sclerosis), and arrhythmia (atrial 
fibrillation).10  In a study about NAFLD which followed 
up the progress of patients for 8 – 11 years, death 
occurred in 13 – 45% of these patients. The combination 
of NAFLD and  cardiovascular diseases  (25% - 28%) 
was the highest cause of mortality.2 
 NAFLD has a significant correlation with cardio 
metabolic risk factors such as obesity, hypertension, 
dyslipidemia, low insulin-like growth factor-1 (IGF-1), 
increase of inflammatory factors and hemostasis in 
plasma, insulin resistance, metabolic syndrome, 
endothelial dysfunction, abnormal glucose tolerance, 
and type-2 diabetes mellitus.10,11 Patients with NAFLD 
especially those at an advanced stage of fibrosis will 
exacerbate hepatic and systemic insulin resistance. In 
turn it will induce atherogenic dyslipidemia and release 
multiple inflammatory factors, pro-coagulant, and pro-
fibrinogenic which holds an important role in the 
pathophysiology of cardiovascular complications.12 
 Liver biopsy is currently accepted as the gold 
standard for confirming the degree of inflammation and 
fibrosis in patients with chronic hepatic diseases. 
However, liver biopsy is invasive, expensive, often 
produces samples with high variability and has adhering 
complications. A number of non-invasive methods have 
been developed by combining clinical and serological 
variables that are able to determine the occurrence of 
advanced fibrosis in patients with NAFLD.13 NAFLD 
fibrosis score (NFS) is one of the non-invasive methods 
that has been validated in its application for determining 
the degree of liver fibrosis in patients with NAFLD. NFS 
has been recommended by the American Association for 
Study of Liver Disease (AASLD), American College of 
Gastroenterology (ACG), American Gastroenterological 
Association (AGA) and by the European Association for 
the Study of the Liver (EASL).13,14   
 NAFLD is known to be a risk factor for the 
occurrence of subclinical abnormalities in myocardial 
metabolism and is associated with subclinical changes 
over time in left ventricular structure function, which 
causes both structural and functional heart 
abnormalities.14 Left ventricular mass index (LVMI) is 
an adjusted mass of the left ventricle to the total surface 
area of the body. This measurement is frequently used as 
a parameter in examining geometrical changes of the left 
ventricle.12,15–17 A study about the measurement of 
LVMI using echocardiography M-Mode, showed that 
patients with NAFLD has a higher value of LVMI than 
the normal population.18  
 Treeprasertsuk et al. 2013 and Kim et al.2013 
revealed that advance fibrosis determined by NFS was a 
significant predictor for mortality, especially regarding 
cardiovascular incidents in patients diagnosed with 
NAFLD through ultrasonography.19,20 Studies by Giorgio 
et al. in 2014 showed that patients with moderate and 
high value of NFS has a significant correlation with an 
increase of LVMI.1 However, research like this have 
never been done in Indonesia, especially in Central Java 
where the incidence of NAFLD is quite high with higher 
probability of cardiovascular disease. While there are 
many similarities between patients with NAFLD from 
Asia and the West, there are several features which may 
differentiate the patients with NAFLD from Asia, such as 
BMI, comorbidities, and genetic factors.9 Therefore, In 
this research we will assess the correlation between 
NAFLD Fibrosis Score (NFS) with Left Ventricular 
Mass Index (LVMI) of patients with NAFLD in dr 
Kariadi Hospital Semarang. This study also aimed to look 
for clinical characteristics of NAFLD in Semarang 
population compared to Western population. 
 
MATERIALS AND METHODS 
 This analytical cross-sectional study was conducted 
at the Department of Gastroenterology and Hepatology, 
dr. Kariadi Hospital Semarang between October 2015 
and September 2016. Subjects were patients of the 
Gastroenterology and Hepatology out-patient clinic that 
fulfilled the inclusion criteria. The inclusion criteria for 
this study were patients with no history of alcohol 
consumption or have history of alcohol consumption 
under 20 grams/day for women and 30 grams/day for 
men, age   18 years old, and was diagnosed with 
NAFLD by ultrasonography with or without biopsy. The 
exclusion criteria were hepatitis due to viral infection, 
alcoholic liver disease, consumption of medicines which 
may lead to a fatty liver, other liver diseases, arteritis or 
connective tissue disorders, renal, thyroid, and 
cardiovascular diseases.  
 Subjects were collected through consecutive 
sampling, and the sample size was calculated using 
correlation coefficient in cross sectional research with 
minimum sample size was 57 patients. The study  was 
approved by the  Ethics Committee  of Faculty of 
Medicine Universitas Diponegoro and dr. Kariadi 
Hospital number 533/EC/FK-RSDK/2015 and was   
conducted   according   to   the  Declaration   of  Helsinki.  
We provided detailed information on the study procedure 
to the patients, followed by written informed consent 
from the subjects. 
 64 patients were enrolled.  Interview and physical 
examinations comprise of vital signs, body weight, 
height, body mass index, hip circumference, cardiac, and 
abdominal examinations. Other examination such as 
echocardiography M-mode, blood (routine blood count, 
urea, creatinine, lipid profile, uric acid, AST, ALT, 
albumin, fasting blood glucose, HBsAg, anti HCV, and 
post prandial blood sugar) and urine examinations were 
obtained. NAFLD fibrosis score was calculated using an 
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RESULTS  
Patient Characteristics 
 From the period of October 2015 to September 2016, 
64 patients fulfilled the inclusion criteria. The basic 
characteristics of these 64 patients was presented on 
Figure 1. 19 patients (29.7%) were <50 years old and 45 
patients (70.3%) were >50 years old with gender 
distribution of 29 females (45.3%) and 35 males 
(54.7%). This study showed that the subjects suffering 
from NAFLD was dominated by males (54.7% males vs 
45.3% females) with average age distribution between 
55 ± 10 years. 
 There were some comorbidities found on all samples 
(64 patients) in the gastroenterology and hepatology out-
patient clinic in Kariadi Hospital; overweight (89.1%) 
was discovered as the most frequent comorbid followed 
by dyslipidemia (81.3%), increase in abdominal 
circumference (70.3%), increase in ratio of AST/ALT 
(56.3%), metabolic syndrome according to IDF 2006 
(56.3%), hypertension (34.4%), and diabetes (25%). 
Ratio of AST/ALT was an interesting discovered in our 
study. 56.3% of our subjects have >1 ratio which 
indicates the chronicity of liver disease in patients. 
Figure 2 shows the comorbidities of these data. 
 
Respondent Distribution based on NFS and LVMI 
degree 
 Subjects were divided into 3 groups in accordance 
with their NAFLD fibrosis score (NFS) : low probability 
group consisting of 10 patients (15.6%), intermediate 
probability group consisting of 22 patients (33.4%), and 
high probability group consisting 32 patients (50%). An 
increase in LVMI found in 44 patients (68.7%). The 
LVMI increased in 1 patient in the low probability group, 
13 patients in the intermediate probability group, and 30 
patients in the high probability group. Figure 3 shows the 
distribution of these data. 
Bivariate Analysis 
Correlation between NFS and LVMI 
 Spearman’s Correlation analysis showed a positive 
correlation between NFS and LVMI (P 0.002 r 0.377) as 
displayed in Table 1. Figure 4 shows a scatter gram 
representing the correlation between NFS and LVMI. 
This study discovered that an increase of LVMI occurred 
in patients with an intermediate or high probability NFS 
score, thus a higher degree of NFS will cause a more 
significant increase of LVMI. 
 Based on bivariate analysis, this study showed that 
cardiovascular risk profile increases in accordance with 
NFS score. High probability patients have the worst 
cardiovascular risk profile. This risk profile gradually 
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Figure 3. Distribution of respondents according to Non-Alcoholic 
Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) and Left 
Ventricular Mass Index (LVMI) 
 
 
Figure 4. Scatter gram and regression line of Non-Alcoholic 
Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) in 
comparison with Left Ventricular Mass Index (LVMI) 
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Confounding Factors Correlation with LVMI 
 Comorbidities were categorized as confounding 
factors that also leads to an increased LVMI. 
Confounding factors that increased LVMI were gender 
and hypertension. In this research, Further analysis done 
by using Mann-Whitney analysis discovered that gender 
was the only confounding factor that have a significant 
effect on LVMI (p<0.25), as displayed in Table 2.  
 
Multivariate Analysis 
Multivariate analysis was done to explore the correlation 
between dependent and independent variables. Bivariate 
analysis showed that gender was one of the variables 
correlated with an increased LVMI. Multivariate 
analysis using the Enter method showed that NFS was 
more influential in increasing LVMI than gender (P 
0.002) as showed in Table 3. 
DISCUSSION  
 From this analytical cross-sectional study of NFS and 
LVMI in NAFLD patient, it was discovered that the 
characteristics of the subject were dominated by males. 
Gender is currently considered as a risk factor of 
NAFLD.1 Incidence rate of NAFLD was higher in >50 
years old group with 2:1 ratio when compared with <50 
years old group. This is in line with previous study by 
Lesmana et al. and Lisa et al. who also found that the 
participants with NAFLD was more likely to be male 
(54.7% versus 37.9%) and were similar in age with a 
mean of 50.4 years.7,14  
 Overweight was the most common comorbid. The 
rationale is that in an inflammatory state, fat 
accumulation in the lower abdomen will stimulate a pro-
inflammatory cytokine release which contributes to the 
pathophysiology of NAFLD.21,22 Purnomo et al. and 
Adams et al. reported an increased prevalence of 
NAFLD in accordance with an increased BMI. 23,24 
Study by Makker et al. also found that waist 
circumference, transaminases levels, and left ventricle 
mass were highest in patients with severe NAFLD and 
NAFLD with Metabolic syndromes combined.25 
 A study done by Hong et al. showed that the 
prevalence of dyslipidemia was 66.8%, which was almost 
similar to our results. It was discovered that 
hypertriglyceridemia (80.4%) and a decrease in HDL 
(77.5%) were the two most common findings. 
Dyslipidemia is a risk factor and also a contributing 
factor that exacerbate the progressivity of NAFLD.26 
Beside fatty acids and triglycerides, evidence showed an 
increased accumulation of free cholesterol in the liver 
with subsequent toxic effects contributing to liver 
damage.10 Our study also discovered 34.4% of subjects 
suffered from hypertension. It is one of the more 
influential metabolic syndromes that contributes towards 
the pathogenesis of NAFLD and a risk factor of 
cardiovascular abnormality.27  
 Ratio of AST/ALT >1 in this study indicated the 
chronicity of liver disease in patients and reflects the 
severe progression of NAFLD.28 NAFLD typically is 
characterized by a hepatocellular pattern of liver-related 
enzymes with mild elevations (1-2 times the upper limit 
of normal) in serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST).28AST/ALT ratio has 
been proposed to predict progressive fibrosis in NAFLD. 
Angulo et al, suggested AST/ALT ratio > 1 reflects the 
severe progression of NAFLD.29 
 Several study have shown that diabetes was one of the 
main risk factors of NAFLD. This was different 
compared to our study where diabetes was only found on 
25% of the subjects.26,30,31 This difference might be 
caused by a novel opinion that NAFLD is also a risk 
factor for diabetes. This opinion is supported by a study 
of Jonathan et al. that showed 73% of NAFLD patients 
developed diabetes later in their life. NAFLD and 
diabetes can influence one another. Scientific reports by 
Alexander et al. showed that diabetes was associated with 
an increased risk of NAFLD and myocardial dysfunction. 
From this reports, 54% of NAFLD patients had a NAFLD 
fibrosis score consistent with advance fibrosis. 32  
 In line with previous study, a recent epidemiological 
studies showed an increase in cardiovascular diseases in 
patients with NAFLD with no history of traditional risk 
factors and metabolic syndrome.33 This was caused by a 
complex interaction between NAFLD, insulin resistance, 
and visceral obesity which leads to an increased risk of 
cardiovascular diseases in patients with NAFLD. NASH 
exacerbates hepatic and systemic insulin resistance that 
causes atherogenic dyslipidemia which is commonly 
presented with an increase of TG, small dense LDL, and 
decrease of HDL. NASH also exacerbates the production 
of pro-inflammatory cytokines (C-reactive protein, 
interleukin-6, tumor necrosis factor-alpha), pro-oxidant 
molecules (oxidized LDL, nitro tyrosine, thiobarbituric 
acid-reacting substances), and pro-fibrinogenic 
mediators (tumor growth factor-beta, insulin like growth 
factor-1, endothelin-1).  Release of components from the 
renin-angiotensin-aldosterone system that usually occurs 
in hypertensive patients was also found in NALFD 
patients.1,33 
 NASH also caused abnormalities in hepatitis m-RNA 
expression with mediators that are responsible for 
vascular and cardiac injuries. This strengthens the theory 
that the increase in factors stated above were caused by 
hepatic cells that underwent steatosis and inflammation. 
6,12 
Table 1. Positive correlation between Non-Alcoholic Fatty 
Liver Disease (NAFLD) Fibrosis Score (NFS) and Left 
Ventricular Mass Index (LVMI) 
Variable P r 
NFS – LVMI 0.002* 0.377 
* Spearman’s Correlation 
 
Table 2. The Correlation between confounding factors with 
Left Ventricular Mass Index (LVMI) 
Variable LVMI P 
Med ± SD 
Gender Man 118±28 0.04* 
 Woman 107±25 
Hypertension + 113±26 0.815* 
 - 109±27 
*Mann-Whitney 
 
Table 3. Multivariate analysis  
Variable UC SC  
B S.E Beta t Sig 
NFS 6.647 2.022 0.395 3.287 0.002* 
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 Experimental studies also discovered that a number 
of gen (PNPLA3-I148M, MBOAT7, GCKR and 
HSD17B13),  which were involved in the metabolism of 
fatty acid, lipolysis, coagulation, monocyte and 
macrophage regulation, and also inflammatory response 
experienced an overt expression in patients with 
NASH.12,13 Biological factors secreted by the liver also 
holds a significant role in structural remodeling and 
geometrical abnormalities of the heart.34 
 Increase of LVMI occurred in patients with an 
intermediate and high probability NFS score. This result 
was similar to Giorgio et al. study that discovered the 
increase of LVMI was not occur in patients with a low 
probability NFS. A cohort study by Kim et al. found that 
241 patients with NAFLD also had an alteration in the 
geometry of the left ventricle and early diastolic 
disfunction. The severity of NFS and the increase of 
LVMI goes in concord.2,35   
 Chun-on et al. found a strong association between 
NFS with CHD, CHF, and CVD because these scores 
detect patients with more advanced disease and liver 
fibrosis.36,37 Hokyou et al. found that subject with 
advanced liver fibrosis exhibited a significantly higher 
prevalence of left ventricular diastolic dysfunction 
compared with those without steatosis.38 Kuang et al 
showed that the correlation between NAFLD and 
cardiovascular diseases are not linked to traditional risk 
factors of cardiovascular diseases and metabolic 
syndrome.39  NFS contains liver-specific variables, AST 
and ALT, or together with other shared risk factors, it is 
suggesting the perspective that liver enzymes AST and 
ALT may play a significant and independent role in the 
pathophysiological mechanism mediating the 
occurrence of the Cardiovascular abnormality.40 
Therefore, NFS as a non-invasive method for detecting 
advanced fibrosis could also be used as an indicator to 
predict the increase of LVMI in NAFLD patients. 
 However, there were some limitations to this study. 
Sample collection and NFS calculation were only done 
once without further follow up even though the 
progressivity of liver fibrosis could affect calculation. 
Fibrosis scoring was also done with a single scoring tool 
without any comparison with other methods. The 
diagnosis of fibrosis was also not confirmed with 
histopathological biopsy. It is necessary to conduct this 
study with conducting subgroup analysis in each group 
according to the degree of NFS using healthy controls 
and a prospective cohort study method. 
 
CONCLUSION 
 A significant positive correlation was showed 
between NFS score and LVMI in patients with NAFLD. 
NFS score might be useful as a predictor for 
cardiovascular outcome in NAFLD patients. 
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